Life Extension Update
Tuesday, March 20, 2012. An article published on February 1, 2012 in advance of print in the European Heart Journal reports a favorable effect for low dose omega-3 fatty acids on the risk of cardiovascular events, including heart attack, cardiac arrest and stroke, in patients with a history of heart attack who did not use statin drugs.
The current study included 3,740 men and women using statin drugs and 413 non-users who participated in the Alpha Omega Trial, which tested the effects of 400 milligrams per day of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 2 grams per day of the omega-3 fatty acid alpha-linolenic acid (ALA), EPA/DHA plus alpha-linolenic acid, or a placebo on the risk of major cardiovascular events in post-heart attack patients between the ages of 60 and 80 years. Participants were enrolled from 2002 through 2006 and were followed for an average of 41 months.
Over the follow-up period, 13 percent of statin users and 15 percent of non-statin users experienced a major cardiovascular event. While neither EPA/DHA and/or ALA reduced cardiovascular events compared to the placebo in those who used statins, among those who did not use the drugs, consuming all three omega-3 fatty acids was associated with less than half the rate of experiencing an event compared to placebo. In their introduction to the article, Daan Kromhout and colleagues note that, "Although adding omega-3 fatty acids to statin therapy leads to significant reductions in triglyceride levels, it has also been suggested that the use of guideline-concordant statin therapy dilutes the effects of omega-3 fatty acids such that no additional protective effect is observed. This hypothesis is supported by the reduction in cardiovascular events through either fatty fish or EPA–DHA in trials in which less than one-third of the participants were on statin therapy."
"The present study indicates that low-dose supplementation with omega-3 fatty acids might reduce the risk of major cardiovascular events in statin non-users with a history of myocardial infarction," the authors conclude. "These results contribute to the explanation of the inconsistent results on the effects of omega-3 fatty acids in secondary prevention trials."
Crominex®3+ is a registered trademark of Natreon, Inc. CinSulin® is a registered trademark of Tang-An Medical Ltd., manufactured under US patent #6,200,569. InSea2® is a registered trademark of innoVactiv™
This supplement should be taken in conjunction with a healthy diet and regular exercise program. Individual results are not guaranteed and results may vary.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.
If you are not 100% satisfied with any purchase made directly from Life Extension®, just return your purchase within 12 months of original purchase date and we will either replace the product for you, credit your original payment method or credit your Life Extension account for the full amount of the original purchase price (less shipping and handling).
These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.